Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts - Test2 - elhamkhani - TriplyDB

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

http://www.wikidata.org/entity/Q24651331

about

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases In 2014, can we do better than CA125 in the early detection of ovarian cancer?LC-MS analysis of estradiol in human serum and endometrial tissue: Comparison of electrospray ionization, atmospheric pressure chemical ionization and atmospheric pressure photoionization.Ovarian cancer biomarkers for molecular biosensors and translational medicine.Ovarian cystectomy in endometriomas: Combined approach.Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review.Serum Human Epididymis Protein 4 (HE4) in the Differential Diagnosis of Peritoneal Tuberculosis: A Report of Two Cases.HE4 as a biomarker for ovarian and endometrial cancer management.HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Current state of biomarker development for clinical application in epithelial ovarian cancer.Proteomic identification of fucosylated haptoglobin alpha isoforms in ascitic fluids and its localization in ovarian carcinoma tissues from Mexican patients.Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer.The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer Comparison of specific ovarian tumor markers by elecsys analyzer 2010 Human epididymis protein 4 reference limits and natural variation in a Nordic reference population Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer Recent advances in the biomarkers for epithelial ovarian cancer.Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes.Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma.Multianalyte assay systems in the differential diagnosis of ovarian cancer.A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance.High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines Biomarker testing for ovarian cancer: clinical utility of multiplex assays The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer.Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.Anti-HE4 antibodies in infertile women and women with ovarian cancer.Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study.Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass Ovarian cancer pathogenesis: a model in evolution.

P2860

Q24634978-0317ECDF-B84F-4A67-A4CF-A3FB0384C551 Q26765913-6A0D53CD-9BF5-46A4-BC3F-316102EA8831 Q26825152-425D8807-7C91-40DF-8935-E3E6A7E514F5 Q33459365-944305E3-49AD-439D-8135-4DD0012AC3A5 Q34150097-6A0B88FC-DDC7-4394-BF73-9F68ECAEA5ED Q34330432-C937CFB6-D127-4CBF-85D3-1F8D46EB8C34 Q34370883-F7884434-313A-48ED-BF9B-5A54BD7E2901 Q34378962-8D398A4E-522A-438C-B166-B7B195AD98AF Q34611530-63A1DEF8-4522-4EE6-89C6-B296C60343E3 Q34621826-F9C0E479-48D1-4690-9620-33EC4F7126D1 Q35006871-686C140A-6264-4857-9472-1B406ED05131 Q35017292-D7EDE068-EBC4-4C06-B8EA-FC98F6405D0E Q35021181-DAA6D35D-1C21-42C4-9D6C-462523D228A6 Q35100951-6D2B3FB0-8FE3-4840-BA9A-CCE4A141EDC8 Q35104034-8CBDE90F-18FD-49E5-A46C-0A7C6B0D2D85 Q35402326-95FB3D3A-5A86-468E-B208-26920AB1D1EB Q35596885-EB687B14-CCF9-4FA9-9281-871E0EF94598 Q35601405-FE1E6248-8307-4D31-979A-4C55EB3893EA Q35605987-D0C22E5D-185D-4D8A-8357-C54E14E27AEE Q35612779-C452664A-E2CD-415D-BE3A-87753719CB71 Q35648196-E37BA241-7504-4245-8A49-786467EBEC41 Q35663613-3F3FCDB2-F643-4647-96B1-DF1F101879A5 Q35663640-134266C2-B459-4562-BE83-A115A5F2CBDD Q35679368-632F47AE-AE6C-43E9-81DC-191B0C98A778 Q35812813-577055B4-9151-4BA1-B5F4-847595AB04B7 Q35854476-2F3177B9-B5B3-4E18-9AAD-47C3713B9EDC Q35956341-45BB61DE-7B80-4469-A795-D9FEA54B9969 Q36058736-E70DF998-95D1-458D-BC2C-F8BB253341E4 Q36346403-A70178C9-36EB-423C-A024-76E162ECE821 Q36361428-A718DF4C-7E94-4C63-A4FC-182CA8786392 Q36674049-8757B5F5-80D3-479E-8FB0-E8D1DEF421E2 Q36752512-F18DF1D6-CC78-4F83-BAB8-3AF069932EDE Q36790307-F0D5FE82-2243-4E25-BD58-0326CE4E7BF0 Q36897149-9D629DF1-18A1-4BDF-92BD-275464931E6D Q36982622-7ED951C7-2464-4BEB-868F-458381C90D90 Q37053905-B3D6F6EE-572F-4076-9EE0-95EEE96C0190 Q37107033-A7A80F3E-4EA9-4A9C-906A-D1A6D42D0FE0 Q37200036-543072A9-C46F-41F9-A5C1-2E482D168DD6 Q37201766-80E69A35-E1FD-4D4C-A7E0-13CDF1ED2FEA Q37335660-6CDD8CEC-73A8-494A-8B20-023D26D6E15B

P2860

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

http://www.wikidata.org/entity/Q24651331

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@ast

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@en

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@nl

type

label

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@ast

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@en

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@nl

prefLabel

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@ast

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@en

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@nl

P1433

Q24651331-699A13C1-763F-455E-8F4F-6C4BFCDC9BA1

P1476

Q24651331-83D0D650-B681-4908-87DD-57F9C9635913

P2093

Q24651331-09856D1E-0943-4557-93E8-E2B7D88CA5B5

Q24651331-114F3474-E124-4D63-88A8-47550DE34EE6

Q24651331-53F6B7A7-FC9B-4D5C-A48F-C946D227CEBB

Q24651331-57B63B68-63D0-401C-A54F-08CC5935C559

Q24651331-7696EA48-4CD2-484A-A0A1-6120B1F38761

Q24651331-8D54075F-B526-412F-8CE8-3C0D3FF5C514

Q24651331-92A39F95-59C3-43C8-816E-444CB175EAED

Q24651331-A5B53BA6-0FD7-42E7-B430-DB4D3279BBE6

Q24651331-B9C3E9BD-24F1-4229-BEDD-F2AD65D9A69C

Q24651331-C2909013-FCE5-42FB-B1FF-D62309D4D917

P2860

Q24651331-269EF3B6-980B-4207-BCCE-7BD2AA3CCA71

Q24651331-2939DEFF-E53A-49A8-9FF8-119996AEC218

Q24651331-4341C00A-1178-4027-B7C1-5A8B2A3E7D31

Q24651331-55CC5A8D-C764-4912-AA5F-2FE4A3668FB6

Q24651331-570B3679-38E0-4B88-863E-4B809A53A2BA

Q24651331-58D2C6E4-B26B-4C03-9C57-99AF0AEAAD9C

Q24651331-595D113A-660A-4F44-92F2-3A46308CF2EA

Q24651331-5E131258-CE9D-46E4-8C42-E3F0E0803504

Q24651331-84CCD92A-0D73-4F1E-9908-A0DEE55CDEE4

Q24651331-934DC2D9-D41E-44A6-B117-BFED394C3614

P2888

Q24651331-15121921-51AA-4F66-831F-C6C61DFCF620

P304

Q24651331-7CA5BB9C-97DD-48E3-BF46-AF25A7FD0A3C

P31

Q24651331-CC5D1023-310F-4A9A-910F-101011E583E8

P356

Q24651331-AF8C211E-7B14-4659-AD4C-09C8E2EB16CC

P407

Q24651331-C4DD687C-A6C7-4C4B-8579-90F30B7EE729

P433

Q24651331-5012E9FD-19FE-42CD-BC38-5C96D2042CE1

P478

Q24651331-ED98D9C0-102E-45FE-9D72-5037538BD48C

P577

Q24651331-72F4233C-E37E-43C0-BFE4-9EFFCB157860

P5875

Q24651331-621C0543-2EC1-4371-8207-3196ECE943D0

P6179

Q24651331-F36B2B16-CAD2-4A93-989D-AD7D3D31C504

P698

Q24651331-2563A3C1-1E51-4082-82CD-55DAA39B2FB7

P932

Q24651331-DB3274B3-C1DC-416A-9F9F-CCDAE54EDF21

P356

P1433

British Journal of Cancer

P1476

Serum HE4 concentration differ ...... om ovarian endometriotic cysts

@en

P2093

A Auranen

http://www.w3.org/2001/XMLSchema#string

A Perheentupa

http://www.w3.org/2001/XMLSchema#string

H Kujari

http://www.w3.org/2001/XMLSchema#string

J Fraser

http://www.w3.org/2001/XMLSchema#string

J Hiissa

http://www.w3.org/2001/XMLSchema#string

J Huvila

http://www.w3.org/2001/XMLSchema#string

J Jalkanen

http://www.w3.org/2001/XMLSchema#string

J Junnila

http://www.w3.org/2001/XMLSchema#string

J Mäkinen

http://www.w3.org/2001/XMLSchema#string

K Huhtinen

http://www.w3.org/2001/XMLSchema#string

P2860

SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other

Comprehensive analysis of HE4 expression in normal and malignant human tissues.

Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.

FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology.

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Endometriosis and ovarian cancer: thoughts on shared pathophysiology.

Blood and urine markers for ovarian cancer: a comprehensive review.

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

P2888

P304

1315-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605011

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24249028

http://www.w3.org/2001/XMLSchema#string

P6179

1039971354

http://www.w3.org/2001/XMLSchema#string

P698

19337252

http://www.w3.org/2001/XMLSchema#string

P932

2676558

http://www.w3.org/2001/XMLSchema#string